Scientists Study Tanezumab as a Relief From Lower Back Pain

lower back pain
The Telegraph

Sustained lower back pain is a major cause of disabilities worldwide. It may arise due to injuries, disease, or stresses on different structures of the body. The patient may feel it as bone pain, nerve pain, or muscle pain.

The latest study shows that a drug, tanezumab, can give long-term relief to chronic low back pain.

The study found that a single dose of tanezumab delivered under the skin every two months can give a relief to back pain.

John Markman, leader of the Translational Pain Research Program in the neurosurgery department at URMC, said that this illustration of efficiency is a significant discovery in the global quest. Consequently, generating non-opioid medications for prolonged pain.

He also said that they noted advancements in function linkage to decrease in pain sharpness.

The study included testing in 8 countries at 191 different places.

The researchers found that specific proteins in the plasma increased the responsiveness of cells in the nervous system which led to pain.

Terminology for one of those proteins is nerve growth factor (NGF). It could explain why few people suffer more persistent back pain. Moreover, Tanezumab is an inhibitor for NGF.


The examiners gave the participants at least three other medicines before the study and they did not feel any relief. They also tested Opioids but it didn’t work. The patients were deemed challenging to treat.

Also Read: A New Technology Increases Hope For An Implantable Artificial Kidney

Patients who had x-ray proof, symptoms, or signs of mild-to-critical osteoarthritis were not a part of the study. Researchers have mostly observed osteoarthritis in older people who have persistent lower back pain.

Tanezumab also had no serious side effects with opioids or non-steroidal anti-inflammatory drugs (NSAIDS). Experts often recommend these drugs to treat lower back pain. Nevertheless, the type of medicines is beneficial for joint problems. Sometimes it makes joint replacement necessary.

To check for this problem, the researchers observed the participants for a longer period. The researchers found no evidence for severe joint difficulties or any need for joint replacement.

Markman says that in the near future, health care workers could have to talk about the several risks associated with lumbar fusion surgery, prolonged opioid usage, or NSAYSs facing the unprecedented dangers of a rare but quickly growing form of joint difficulty linked with obstructing nerve maturity determinant.

The study tested many drugs and results suggest that only tanezumab is safe. The researchers observed the patients for a course of 56 weeks. They also observed for a 24 weeks safety follow up.


Earlier this year, Pfizer Global Product Development had conducted another similar study.

Ken Verburg, tanezumab developing team head, Pfizer Global Product Development. said that this is easily one of the longest research experimented yet, on persistent lower back pain. However, they await further analysis of their findings and expect that the results will support the future they have planned – The regulatory submissions in prolonged lower back pain, globally.

Tanezumab did not prove to lead to addiction, misuse, or dependence during the study. The other 3 drugs had some side effects and were not as useful as tanezumab.